Meta-analysis of microarray data on pancreatic cancer defines a set of commonly dysregulated genes

Abstract

Pancreatic ductal adenocarcinoma is the eighth most common cancer with the lowest overall 5-year relative survival rate of any tumor type today. Expression profiling using microarrays has been widely used to identify genes associated with pancreatic cancer development. To extract maximum value from the available gene expression data, we applied a meta-analysis to search for commonly differentially expressed genes in pancreatic ductal adenocarcinoma. We obtained data sets from four different gene expression studies on pancreatic cancer. We selected a consensus set of 2984 genes measured in all four studies and applied a meta-analysis approach to evaluate the combined data. Of the genes identified as differentially expressed, several were validated using RT-PCR and immunohistochemistry. Additionally, we used a class discovery algorithm to identify a gene expression signature. Our meta-analysis revealed that the pancreatic cancer gene expression data sets shared a significant number of up-and downregulated genes, independent of the technology used. This interstudy crossvalidation approach generated a set of 568 genes that were consistently and significantly dysregulated in pancreatic cancer. Of these, 364 (64.1%) were upregulated and 204 (35.9%) were downregulated in pancreatic cancer. Only 127 (22%) were described in the published individual analyses. Functional annotation of the genes revealed that genes presumably associated with the cell adhesionmediated drug resistance pathway are frequently overexpressed in pancreatic cancer. Meta-analysis is an important tool for the identification and validation of differentially expressed genes. These could represent good candidates for novel diagnostic and therapeutic approaches to pancreatic cancer.

Sperm-associated antigen 1 is expressed early in pancreatic tumorigenesis and promotes motility of cancer cells

“…We and others have recently undertaken such analyses of normal pancreas and pancreatic adenocarcinoma (Crnogorac-Jurcevic et al, 2003;Logsdon et al, 2003;Hustinx et al, 2004;Grutzmann et al, 2005) and our cDNA array data showed overexpression of spermassociated antigen 1 (SPAG1) in cancer cells (Missiaglia et al, 2004).…”

Gene expression profiles of progressive pancreatic endocrine tumours and their liver metastases reveal potential novel markers and therapeutic targets

“…8), is a transmembrane protein expressed by several bone marrow stromal cell lines and fibroblasts (Ishikawa et al 1995), and overexpressed in myeloma cells and in several solid tumour cell lines showing elevated invasive capacity (Walter-Yohrling et al 2003). Overexpression of BST2 has also been described in pancreatic adenocarcinoma in a recent meta-analysis of expression profile studies (Grutzmann et al 2005). Notably, a humanised anti-HM1.24 antibody has been developed and employed in clinical trials of multiple myeloma patients (Ozaki et al 1999), and immunotherapy against HM1.24 is being developed (Rew et al 2005).…”

Human pancreatic tumor cells are sensitized to ionizing radiation by knockdown of caveolin-1

“…In contrast to previous studies analysing whole tissue samples from pancreatic tumors (IacobuzioDonahue et al, 2003;Grutzmann et al, 2005), we analysed expression of Cav-1 and related signaling molecules in microdissected tissues of normal pancreatic epithelia versus ductal pancreatic adenocarcinoma (Grutzmann et al, 2004). Expression of the genes of interest was measured in eight pancreatic cancer cell lines, seven normal pancreatic epithelia and 11 ductal adenocarcinoma.…”